Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: One year, double blind, randomised, comparative trial

British Medical Journal

Volumn 327, Issue 7420, 2003, Pages 891-895

  Bjermer, Leif ^a   Bisgaard, Hans ^b   Bousquet, Jean ^c   Fabbri, Leonardo M ^d   Greening, Andrew P ^e   Haahtela, Tari ^f   Holgate, Stephen T ^g   Picado, Cesar ^h   Menten, Joris ⁱ   Dass, S Blachandra ⁱ   Leff, Jonathan A ⁱ   Polos, Peter G ⁱ  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c HÔPITAL ARNAUD DE VILLENEUVE   (France)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e WESTERN GENERAL HOSPITAL   (United Kingdom)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^h UNIVERSITY OF BARCELONA   (Spain)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; FLUTICASONE PROPIONATE; MONTELUKAST; SALMETEROL;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHIL; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NOCTURNAL ASTHMA; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; TREATMENT OUTCOME;

ACETATES; ADOLESCENT; ADULT; AGED; ALBUTEROL; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FORCED EXPIRATORY VOLUME; HUMANS; MIDDLE AGED; QUINOLINES; TREATMENT OUTCOME;

EID: 0142074290     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. National Institutes of Health, National Heart, Lung and Blood Institute. Asthma management and prevention. Global initiative for asthma. A practical guide for public health officials and health care professionals. Based on the global strategy for asthma management and prevention NHLBI/WHO workshop report. Bethesda, MD: NIH, 1995. (NIH publication No. 96-3659A.) Updated report 2002. www.ginasthma.com (accessed 28 Aug 2003).
2. British asthma guidelines coordinating committee. British guidelines on asthma management: 1995 review and position statement. Thorax 1997;52:S1-24.
3. El-Radhi AS, Hogg CL, Bungre JK, Bush A, Corrigan CJ. Effect of oral glucocorticoid treatment on serum inflammatory markers in acute asthma. Arch Dis Child 2000;83:158-62.
4. Laviolette M, Malmstrom K, Lu S, Chervinsky P, Pujet JC, Peszek I, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med 1999;160:1862-8.
5. Brazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999;340:197-206.
6. Pizzichini E, Leff JA, Reiss TF, Hendele L, Boulet LP, Wei LX, et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J 1999;14:12-8.
7. Reiss TF, Sorkness CA, Stricker W, Botto A, Busse WW, Kundu S, Zhang J. Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax 1997;52:45-8.
8. Villaran C, O'Neill SJ, Helbling A, van Noord JA, Lee TH, Chuchalin AG, et al. Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group. J Allergy Clin Immunol 1999;104:547-53.
9. Juniper, EF, Guyatt, GH, Willan, A, Griffith LE. Determining a minimal important change in a disease specific quality of life questionnaire. J Clin Epidemiol 1994;47:81-7.
10. Metso T, Rytilä P, Peterson C, Haahtela T. Granulocyte markers in induced sputum in patients with respiratory disorders and healthy persons obtained by two sputum-processing methods. Respir Med 2001;95:48-55.
11. Pauwels RA, Löfdahl C-G, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ. et al. Effect of inhaled formeterol and budesonide on exacerbations of asthma. N Engl Med 1997;337:1405-11.
12. Dworski R, Fitzgerald GA, Oates JA, Sheller JR. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 1994;149:953-9.
13. O'Shaughnessy KM, Wellings R, Gillies B, Fuller RW. Differential effects of fluticasone propionate on allergen-evoked bronchoconstriction and increased urinary leukotriene E4 excretion. Am Rev Respir Dis 1993;147:1472-6.
14. Fish JE, Israel E, Murray JJ, Emmett A, Boone R, Yancey SW, Rickard KA. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest 2001;120:423-30.
15. Nelson HS, Busse WW, Kerwin E, Church N, Emmett A, Rickard K, Knobil K. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000;106:1088-95.
16. Kraft M, Pak J, Martin RJ, Kaminsky D, Irvin CG. Distal lung dysfunction at night in nocturnal asthma. Am J Respir Crit Care Med 2001;163:1551-6.
17. Minoguchi K, Kohno Y, Minoguchi H, Kihara N, Sano Y, Yasuhara H, Adachi M. Reduction of eosinophilic inflammation in the airways of patients with asthma using montelukast. Chest 2002;121:732-8.
18. Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ. Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. Chest 2001b;119:1021-6.
19. Bisgaard H. Long-acting beta(2)-agonists in management of childhood asthma: A critical review of the literature. Pediatr Pulmonol 2000;29:221-34.